CAMBRIDGE, Mass. - eTradeWire -- EyeCool Therapeutics today announced the publication of the first randomized, double‑masked, multicenter clinical trial evaluating its investigational ocular surface cooling device for the treatment of chronic ocular surface pain (COSP) in Ophthalmology and Therapy. The study showed that a single in‑office treatment produced durable and clinically meaningful reductions in eye pain, along with significant improvement in corneal sensitivity, in patients with peripheral‑dominant pain phenotypes.

The trial, "A Randomized Double‑Masked Study Evaluating Safety and Efficacy of a Novel Topical Cooling Device for Chronic Ocular Surface Pain" (Galor et al., Ophthalmol Ther, 2026; doi:10.1007/s40123‑026‑01392‑3), enrolled adults with COSP to receive a one‑time, 4‑minute treatment with either the active or a sham handheld cooling device.

More on eTradeWire News

• Author Joseph M Corrigan Releases, "Patients First."
• Priority Playlist Urban Music Stage Returns To Atlanta With A New Wave Of Independent Talent
• Super Green Environmental Offers Independent Mold Inspection in South Florida
• Will the film series Mad Max become an Actual reality: Water Wars
• Lkpfm corporation Political Fund Raising

In this prospective randomized, double masked controlled study, unilateral treatments were administered to 31 subjects with follow‑up to 8 weeks. Across three patient‑reported outcome measures, the active treatment arm demonstrated greater reductions in eye pain at week 8 than the sham arm, with all three exceeding thresholds for clinically meaningful improvement.

In a pre‑specified post hoc analysis of eyes with peripheral‑dominant pain, defined as a reduction in pain from a proparacaine challenge, eye pain severity improved significantly versus sham at week 8 (nominal p = 0.042) in one instrument, and overall eye pain showed a strong trend toward statistical significance (nominal p = 0.088) in another.

The device was well tolerated, with no serious adverse events reported. The most common adverse event was transient conjunctival hyperemia.

"The publication of this randomized, double‑masked study is an important step for patients living with chronic ocular surface pain," said Anat Galor, MD, MSPH, Bascom Palmer Eye Institute, University of Miami, and lead author of the study. "Not only did we see clinically meaningful improvements across multiple pain instruments, but we also observed that baseline corneal sensitivity, initially below normal in both arms, statistically significantly improved only in the actively treated group. This technology may address a critical unmet need in this population with limited effective options."

More on eTradeWire News

• Jazze Pha Looking For The Next Star With The Launching Pad Music Stage Season One
• Shaun & Jeff Spanos will be attending The Aesthetic Show in fabulous Las Vegas
• Restaurant Hotline Plus Launches Interactive HTML Workbooks for Restaurant Operators
• Georgia Pastor Dr. Jeff Dabbs Expands Christian Thriller Controlled Gospel
• Sponsorship 18th Annual Treasure Coast Marine Flea Market and Boat Sale

About EyeCool Therapeutics Inc.

EyeCool Therapeutics is a clinical stage medical device company committed to innovation and novel therapies for eye care. EyeCool is focused on developing an in-clinic device to deliver fast, lasting relief for patients suffering from Chronic Ocular Surface Pain.

Important Safety Information

Warning: This product has not been approved or cleared for marketing by the U.S. Food and Drug Administration and is considered an investigational device.

For more information, please visit www.eyecooltx.com.